신경학적 바이오마커 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Neurological Biomarkers Market size is expected to reach USD 28.98 Billion in 2034 from USD 11.18 Billion (2025) growing at a CAGR of 11.16% during 2026-2034.

The neurological biomarkers market is advancing rapidly as research institutions and pharmaceutical developers intensify their focus on precision medicine. Biomarkers are becoming instrumental in early diagnosis, drug response monitoring, and therapeutic decision-making for complex neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. With rising investments in clinical trials and molecular diagnostic platforms, the sector is set to benefit from the integration of genomics, proteomics, and imaging technologies. This evolution will not only enhance diagnostic accuracy but also open pathways for personalized interventions, significantly improving patient outcomes.

Digital health tools are further reinforcing the demand for neurological biomarkers, particularly as artificial intelligence and machine learning enable faster interpretation of complex datasets. Wearable devices and digital diagnostics are capturing real-time data on cognitive function and neurophysiological parameters, which can be linked with validated biomarkers for comprehensive disease monitoring. Pharmaceutical pipelines are increasingly embedding biomarkers into trial protocols to identify patient subgroups most likely to respond to targeted therapies, accelerating approval timelines and reducing attrition rates in drug development.

The coming years are expected to witness deeper cross-sector collaborations between biotech firms, diagnostic companies, and healthcare systems to expand biomarker validation and commercialization. As regulatory bodies refine frameworks for biomarker qualification, greater emphasis will be placed on reproducibility and clinical utility. Moreover, the shift toward minimally invasive testing methods, such as liquid biopsies using cerebrospinal fluid or blood-based assays, will drive accessibility and scalability of neurological biomarker testing worldwide. This convergence of innovation and clinical integration positions the market as a cornerstone for the future of neurodegenerative disease management.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Proteomic Biomarkers
• Genomic Biomarkers
• Metabolomic Biomarkers
• Imaging
• Other Biomarker Types

By Disease Type

• Alzheimer's Disease
• Parkinson's Disease
• Autism Spectrum Disorders
• Epilepsy
• Other Diseases

By End Use

• Hospitals and Clinics
• Research Laboratories
• Biopharmaceutical Companies
• Other End Users

COMPANIES PROFILED

• Abbott Laboratories, ACOBIOM, Alseres Pharmaceuticals Inc, Banyan Biomarkers Inc, BioRad Laboratories Inc, DiaGenic ASA, Johnson Johnson, Merck KGaA, QIAGEN NV, Quanterix Corporation, RulesBased Medicine Inc, Thermo Fisher Scientific Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Proteomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Genomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Metabolomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Biomarker Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Alzheimer's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parkinson's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Autism Spectrum Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Epilepsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Disease Type
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Disease Type
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Disease Type
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Disease Type
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Disease Type
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL NEUROLOGICAL BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Abbott Laboratories
  • 9.2.2 ACOBIOM
  • 9.2.3 Alseres Pharmaceuticals Inc
  • 9.2.4 Banyan Biomarkers Inc
  • 9.2.5 Bio-Rad Laboratories Inc
  • 9.2.6 DiaGenic ASA
  • 9.2.7 Johnson & Johnson
  • 9.2.8 Merck KGaA
  • 9.2.9 QIAGEN N.V
  • 9.2.10 Quanterix Corporation
  • 9.2.11 Rules-Based Medicine Inc
  • 9.2.12 Thermo Fisher Scientific Inc